Top

Published in:

01-09-2014 | Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-Prevention

Authors: M.-J. Milloy, Julio S. G. Montaner, Evan Wood

Published in: Current HIV/AIDS Reports | Issue 3/2014

Abstract

Contact with the criminal justice system, including incarceration, is a common experience for many people living with HIV/AIDS. Optimism has recently been expressed that correctional facilities could be important locations for treatment-as-prevention (TasP)-based initiatives. We review recent findings regarding the effect of incarceration on patterns of HIV transmission, testing, treatment initiation and retention. We found that the prevalence of HIV infection among incarcerated individuals remains higher than analogous non-incarcerated populations. Recent studies have shown that voluntary HIV/AIDS testing is feasible in many correctional facilities, although the number of previously undiagnosed individuals identified has been modest. Studies have implied enhanced linkage to HIV/AIDS treatment and care in jails in the United States was associated with improvements in the HIV cascade of care. However, for many individuals living with HIV/AIDS, exposure to the correctional system remains an important barrier to retention in HIV/AIDS treatment and care. Future research should evaluate structural interventions to address these barriers and facilitate the scale-up of TasP-based efforts among individuals living in correctional settings.

Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94:1218–23.PubMedCentralPubMedCrossRef

Rotily M, Weilandt C, Bird SM, Käll K, Van Haastrecht HJ, Iandolo E, et al. Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. Eur J Pub Health. 2001;11:243–50.CrossRef

Allwright S. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ. 2000;321:78–82.PubMedCentralPubMedCrossRef

Amiya RM, Cope JE, Poudel KC, Jimba M. At the intersection of public health and criminal justice systems. Lancet. 2013;381:534.PubMedCrossRef

Centers for Disease Control and Prevention (CDC). HIV transmission among male inmates in a state prison system--Georgia, 1992-2005. MMWR Morb Mortal Wkly Rep. 2006;55:421–6.

Dolan KA, Wodak A. HIV transmission in a prison system in an Australian State. Med J Aust. 1999;171:14–7.PubMed

Taylor A, Goldberg D, Emslie J, Wrench J, Gruer L, Cameron S, et al. Outbreak of HIV infection in a Scottish prison. BMJ. 1995;310:289–92.PubMedCentralPubMedCrossRef

Zack B. Correctional health and the HIV stages of care. J Correct Health Care. 2013;19:229–30.PubMedCrossRef

9.•

Jürgens R, Nowak M, Day M. HIV and incarceration: prisons and detention. J Int AIDS Soc. 2011;14:26. The most comprehensive review of the epidemiological, clinical and policy implications of incarceration among individuals living with/at risk of HIV.PubMedCentralPubMedCrossRef

10.

Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367–87.PubMedCrossRef

11.

Walmsley R. World prison population list. 9th ed. Essex: International Centre for Prison Studies; 2013. p. 1–6.

12.

Incarceration and crime: a complex relationship. Washington, DC: The Sentencing Project; 2005; pp. 1–11.

13.

Blumstein A, Beck AJ. Population growth in US prisons, 1980-1996. Crime Just. 1999;26:17.CrossRef

14.

West H, Sabol WJ, Greenman S. Prisoners in 2009. Washington, DC: United States Department of Justice; 2011. p. 1–38.

15.•

Rich JD, Diclemente R, Levy J, Lyda K, Ruiz MS, Rosen DL, et al. Correctional facilities as partners in reducing HIV disparities. J Acquir Immune Defic Syndr. 2013;63 Suppl 1:S49–53. An important call from leading US-based researchers into correctional health to engage correctional facilities in addressing HIV/AIDS-associated disparities.PubMedCentralPubMedCrossRef

16.

Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA J Am Med Assoc. 2009;301:183–90.CrossRef

17.•

Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013;26:10–6. A review of seek, test, treat and retain campaigns among incarcerated individuals in the United States.PubMedCentralPubMedCrossRef

18.

Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4:A16–21.

19.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCentralPubMedCrossRef

20.

Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532–9.PubMedCentralPubMedCrossRef

21.

Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE. 2012;7:e30216.PubMedCentralPubMedCrossRef

22.

Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531–6.PubMedCrossRef

23.

Draine J, Ahuja D, Altice FL, Arriola KJ, Avery AK, Beckwith CG, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. Aids Care Psychol Socio-Med Asp Aids-Hiv. 2011;23:366–77.

24.

Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53:725–31.PubMedCentralPubMedCrossRef

25.

Milloy M-J, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS. 2012;26:60–7.PubMedCentralPubMedCrossRef

26.

Clatts MC, Rodriguez-Diaz CE, Garcia H, Vargas-Molina RL, Jovet-Toledo GG, Goldsamt LA. Preliminary evidence of significant gaps in continuity of HIV care among excarcerated populations in Puerto Rico. J Int Assoc Physicians AIDS Care (JIAPAC). 2011;10:339–41.CrossRef

27.

Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for ‘treatment as prevention”. Curr Opin HIV AIDS. 2012;7:332–8.PubMedCrossRef

28.

Rich JD, Dickinson BP, Macalino G, Flanigan TP, Towe CW, Spaulding A, et al. Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. JAIDS J Acquir Immune Defic Syndr. 1999;22:161–6.

29.

Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H. Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000;34:431–6.PubMedCrossRef

30.

Tyndall MW, Currie S, Spittal P, Li K, Wood E, O’shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17:887–93.PubMedCrossRef

31.

Choopanya K, Jarlais Des DC, Vanichseni S, Kitayaporn D, Mock PA, Raktham S, et al. Incarceration and risk for HIV infection among injection drug users in Bangkok. JAIDS J Acquir Immune Defic Syndr. 2002;29:86–94.

32.

Reekie JM, Levy MH, Richards AH, Wake CJ, Siddall DA, Beasley HM, et al. Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010. Med J Aust. 2014;200:277–80.PubMedCrossRef

33.•

Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS ONE. 2013;8:e59643. The authors present the results from a representative survey of HIV and related matters among recently-released Ukranian prisoners.PubMedCentralPubMedCrossRef

34.••

Henostroza G, Topp SM, Hatwiinda S, Maggard KR, Phiri W, Harris JB, et al. The high burden of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public health alert. PLoS ONE. 2013;8:e67338. In the first published survey of its kind, the authors present the results of a screening programme for HIV and TB in a large Zambian prison, establishing that correctional-associated HIV transmission and pathogenesis should be an urgent priority in efforts to address the pandemic in Sub-Saharan Africa.PubMedCentralPubMedCrossRef

35.

Mohamed HI, Saad ZM, Abd-Elreheem EM, Abd-ElGhany WM, Mohamed MS, Abd Elnaeem EA, et al. Hepatitis C, hepatitis B and HIV infection among Egyptian prisoners: seroprevalence, risk factors and related chronic liver diseases. J Infect Public Health. 2013;6:186–95.PubMedCrossRef

36.

Semaille C, Le Strat Y, Chiron E, Chemlal K, Valantin MA, Serre P, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18.

37.

Honarvar B, Odoomi N, Moghadami M, Afsar Kazerooni P, Hassanabadi A, Zare Dolatabadi P, et al. Blood-borne hepatitis in opiate users in Iran: a poor outlook and urgent need to change nationwide screening policy. PLoS ONE. 2013;8:e82230.PubMedCentralPubMedCrossRef

38.

Vagenas P, Azbel L, Polonsky M, Kerimi N, Mamyrov M, Dvoryak S, et al. A review of medical and substance use co-morbidities in Central Asian prisons: implications for HIV prevention and treatment. Drug Alcohol Depend. 2013;132 Suppl 1:S25–31.PubMedCrossRef

39.

Telisinghe L, Fielding KL, Malden JL, Hanifa Y, Churchyard GJ, Grant AD, et al. High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. PLoS ONE. 2014;9:e87262.PubMedCentralPubMedCrossRef

40.

Winetsky DE, Almukhamedov O, Pulatov D, Vezhnina N, Dooronbekova A, Zhussupov B. Prevalence, risk factors and social context of active pulmonary tuberculosis among prison inmates in Tajikistan. PLoS ONE. 2014;9:e86046.PubMedCentralPubMedCrossRef

41.

Margolis B, Al-Darraji HAA, Wickersham JA, Kamarulzaman A, Altice FL. Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. Int J Tuberc Lung Dis. 2013;17:1538–44.PubMedCentralPubMedCrossRef

42.

Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91:36–45.PubMedCentralPubMedCrossRef

43.

Milloy M-J, Wood E, Tyndall M, Lai C, Montaner J, Kerr T. Recent incarceration and use of a supervised injection facility in Vancouver, Canada. Addict Res Theory. 2009;17:538–45.CrossRef

44.

Buavirat A. Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ. 2003;326:308.PubMedCentralPubMedCrossRef

45.

Epperson M, El-Bassel N, Gilbert L, Orellana ER, Chang M. Increased HIV risk associated with criminal justice involvement among men on methadone. AIDS Behav. 2007;12:51–7.PubMedCentralPubMedCrossRef

46.

Widman L, Noar SM, Golin CE, Willoughby JF, Crosby R. Incarceration and unstable housing interact to predict sexual risk behaviours among African American STD clinic patients. Int J STD AIDS. 2014;25:348–54.PubMedCrossRef

47.

Brewer RA, Magnus M, Kuo I, Wang L, Liu T-Y, Mayer KH. Exploring the relationship between incarceration and HIV among black men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2014;65:218–25.PubMedCrossRef

48.•

Brewer RA, Magnus M, Kuo I, Wang L, Liu T-Y, Mayer KH. The high prevalence of incarceration history among Black men who have sex with men in the United States: associations and implications. Am J Public Health. 2014;104:448–54. An important analysis of the effects of mass incarceration on Black men who have sex with men in the United States.PubMedCrossRef

49.

Alexander M. The new Jim Crow. The New Press; 2013.

50.

Millett GA, Peterson JL, Wolitski RJ, Stall R. Greater risk for HIV infection of black men who have sex with men: a critical literature review. Am J Public Health. 2006;96:1007–19.PubMedCentralPubMedCrossRef

51.

Halkitis PN, Kapadia F, Siconolfi DE, Moeller RW, Figueroa RP, Barton SC, et al. Individual, psychosocial, and social correlates of unprotected anal intercourse in a new generation of young men who have sex with men in New York City. Am J Public Health. 2013;103:889–95.PubMedCentralPubMedCrossRef

52.

Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 2006;1–17.

53.

Branson BM, Viall A, Marum E. Expanding HIV testing: back to the future. JAIDS J Acquir Immune Defic Syndr. 2013;63:S117.

54.

Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.PubMedCrossRef

55.

Yang Q, Boulos D, Yan P, Zhang F, Remis RS, Schanzer D, et al. Estimates of the number of prevalent and incident human immunodeficiency virus (HIV) infections in Canada, 2008. Can J Public Health. 2010;101:486–90.PubMed

56.

Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA J Am Med Assoc. 2009;301:2380–2.CrossRef

57.•

Gagnon M, Jacob JD, Cormier L. Total control: a critical analysis of mandatory HIV testing in U.S. prisons. J Forensic Nurs. 2013;9:154–61. The authors summarize the substantial ethical, legal and human rights concerns around HIV testing in US correctional settings.PubMedCrossRef

58.

Seal DW, Eldridge GD, Zack B, Sosman J. HIV testing and treatment with correctional populations: people, not prisoners. J Health Care Poor Underserved. 2010;21:977–85.PubMedCentralPubMedCrossRef

59.

HIV testing and counselling in prisons and other closed settings. Geneva: United Nations Office on Drug Control and Crime; 2009 pp. 1–72.

60.

Pope JL. HIV testing in state correctional systems. JL Health. 2009;22:17.

61.

HIV/AIDS prevention, care, treatment and support in prison settings. New York City: United Nations Office on Drugs and Crime; 2006, pp. 1–50.

62.

Spaulding AC, Booker CA, Freeman SH, Ball SW, Stein MS, Jordan AO, et al. Jails, HIV testing, and linkage to care services: an overview of the EnhanceLink initiative. AIDS Behav. 2013;17 Suppl 2:S100–7.PubMedCrossRef

63.

de Voux A, Spaulding AC, Beckwith C, Avery A, Williams C, Messina LC, et al. Early identification of HIV: empirical support for jail-based screening. PLoS ONE. 2012;7.

64.

Beckwith CG, Nunn A, Baucom S, Getachew A, Akinwumi A, Herdman B, et al. Rapid HIV testing in large urban jails. Am J Public Health. 2012;102 Suppl 2:S184–6.PubMedCentralPubMedCrossRef

65.

Centers for Disease Control and Prevention (CDC). Routine HIV screening during intake medical evaluation at a County Jail - Fulton County, Georgia, 2011-2012. MMWR Morb Mortal Wkly Rep. 2013;62:495–7.

66.•

Solomon L, Montague BT, Beckwith CG, Baillargeon J, Costa M, Dumont D, et al. Survey finds that many prisons and jails have room to improve HIV testing and coordination of postrelease treatment. Health Aff (Millwood). 2014;33:434–42. This survey of prison and jail systems in the United States reveals that a low proportion of settings offer HIV testing and linkage consistent with official guidelines.CrossRef

67.

Wohl DA, Golin C, Rosen DL, May JM, White BL. Detection of undiagnosed HIV among state prison entrants. JAMA J Am Med Assoc. 2013;310:2198–9.CrossRef

68.

Springer S, Friedland G, Doros G, Pesanti E, Altice F. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials. 2007;8:205–12.PubMedCentralPubMedCrossRef

69.

Babudieri S, Aceti A, D’Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA J Am Med Assoc. 2000;284:179–80.CrossRef

70.•

Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014. doi:10.1001/jamainternmed.2014.601. This retrospective review of all known individuals living with HIV/AIDS in a US state correctional system found substantial improvements in virologic control during incarceration.PubMedCentral

71.•

Davies N, Karstaedt AS. Antiretroviral outcomes in South African prisoners: a retrospective cohort analysis. PLoS ONE. 2012;7. This small study of individuals in the South African prison system reported virologic outcomes comparable to that observed in high-resource settings.

72.

Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, et al. Accessing antiretroviral therapy following release from prison. JAMA J Am Med Assoc. 2009;301:848–57.CrossRef

73.

Wakeman SE, McKinney ME, Rich JD. Filling the gap: the importance of medicaid continuity for former inmates. J Gen Intern Med. 2009;24:860–2.PubMedCentralPubMedCrossRef

74.

Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356:157–65.PubMedCentralPubMedCrossRef

75.•

Booker CA, Flygare CT, Solomon L, Ball SW, Pustell MR, Bazerman LB, et al. Linkage to HIV care for jail detainees: findings from detention to the first 30 days after release. AIDS Behav. 2013;17 Suppl 2:S128–36. This study identified important correlates of successful linkage following incarceration, including stable housing, in individuals participating in the EnhanceLink initiative.PubMedCrossRef

76.

Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21:708–14.PubMedCrossRef

77.

Milloy M-J, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203:1215–21.PubMedCentralPubMedCrossRef

78.

Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17:539–49.PubMedCrossRef

79.

Milloy M-J, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S, et al. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;59:393–9.PubMedCentralPubMedCrossRef

80.•

Youmans E, Burch J, Moran R, Smith L, Duffus WA. Disease progression and characteristics of HIV-infected women with and without a history of criminal justice involvement. AIDS Behav. 2013;17:2644–53. This study describes how women with a history of involvement in the criminal justice system exhibit faster disease progression.PubMedCrossRef

81.

Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27:2559–66.PubMedCentralPubMedCrossRef

82.

Pecoraro A, Royer-Malvestuto C, Rosenwasser B, Moore K, Howell A, Ma M, et al. Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States. AIDS Care. 2013;25:1399–406.PubMedCrossRef

83.

Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013;133:154–60.PubMedCrossRef

84.

Springer SA, Qiu JJ, Saber-Tehrani AS, Altice FL. retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS ONE. 2012;7.

85.•

Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend. 2013;132:378–82. This study reveals how methadone dose at time of release from prison improved retention in treatment among formerly-incarcerated prisoners in Malaysia.PubMedCrossRef

86.

Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014;37:209–18.PubMedCrossRef

87.

Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. Am J Public Health. 2014;104:434–41.PubMedCentralPubMedCrossRef

88.

Althoff AL, Zelenev A, Meyer JP, Fu J, Brown S-E, Vagenas P, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2013;17 Suppl 2:S156–70.PubMedCrossRef

89.

Avery AK, Ciomcia RW, Lincoln T, Desbrais M, Jordan AO, Rana AI, et al. Jails as an opportunity to increase engagement in HIV care: findings from an observational cross-sectional study. AIDS Behav. 2013;17 Suppl 2:S137–44.PubMedCrossRef

90.

Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, et al. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav. 2013;17:2654–66.PubMedCrossRef

91.

Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, et al. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav. 2013;17 Suppl 2:S118–27.PubMedCrossRef

92.

Jordan AO, Cohen LR, Harriman G, Teixeira PA, Cruzado-Quiñones J, Venters H. Transitional care coordination in New York City jails: facilitating linkages to care for people with HIV returning home from Rikers Island. AIDS Behav. 2013;17 Suppl 2:S212–9.PubMedCrossRef

93.

Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, et al. Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS Behav. 2013;17 Suppl 2:S171–80.PubMedCrossRef

94.

Spaulding AC, Pinkerton SD, Superak H, Cunningham MJ, Resch S, Jordan AO, et al. Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention. AIDS Behav. 2013;17 Suppl 2:S220–6.PubMedCrossRef

95.

Williams CT, Kim S, Meyer J, Spaulding A, Teixeira P, Avery A, et al. Gender differences in baseline health, needs at release, and predictors of care engagement among HIV-positive clients leaving jail. AIDS Behav. 2013;17 Suppl 2:S195–202.PubMedCrossRef

96.

Zelenev A, Marcus R, Kopelev A, Cruzado-Quiñones J, Spaulding A, Desabrais M, et al. Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav. 2013;17 Suppl 2:S181–94.PubMedCrossRef

97.

Spaulding AC, Messina LC, Kim BI, Chung K-W, Lincoln T, Teixeira P, et al. Planning for success predicts virus suppressed: results of a non-controlled, observational study of factors associated with viral suppression among HIV-positive persons following jail release. AIDS Behav. 2013;17 Suppl 2:S203–11.PubMedCrossRef

98.

Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.PubMedCentralPubMedCrossRef

99.

Milloy M-J, Kerr T, Salters K, Samji H, Guillemi S, Montaner J, et al. Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis. BMC Infect Dis. 2013;13:565.PubMedCentralPubMedCrossRef

100.

Prellwitz IM, Alves BM, Ikeda MLR, Kuhleis D, Picon PD, Jarczewski CA, et al. HIV behind bars: human immunodeficiency virus cluster analysis and drug resistance in a reference correctional unit from southern Brazil. PLoS ONE. 2013;8:e69033.PubMedCentralPubMedCrossRef

101.

Menezes P, Rosen D, Wohl DA, Kiziah N, Sebastian J, Eron JJJ, et al. Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States. AIDS Res Hum Retrovir. 2013;29:136–41.PubMedCentralPubMedCrossRef

102.

Montaner JSG, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS ONE. 2014;9:e87872.PubMedCentralPubMedCrossRef

103.

Cescon A, Kanters S, Brumme CJ, Lepik KJ, Forrest JI, Hull M, et al. Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010. J. Acquir Immune Defic Syndr. 2013.

104.

Jürgens R, Betteridge G. Prisoners who inject drugs: public health and human rights imperatives. Health Hum Rights. 2005;8:46–74.PubMedCrossRef

Title: Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-Prevention
Authors: M.-J. Milloy
Julio S. G. Montaner
Evan Wood
Publication date: 01-09-2014
Publisher: Springer US
Published in: Current HIV/AIDS Reports / Issue 3/2014
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-014-0214-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-Prevention

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals

Chronic Inflammation and the Role for Cofactors (Hepatitis C, Drug Abuse, Antiretroviral Drug Toxicity, Aging) in HAND Persistence

Treatment of HIV in the CNS: Effects of Antiretroviral Therapy and the Promise of Non-Antiretroviral Therapeutics

Bone Alterations Associated with HIV

Understanding the Etiology and Management of HIV-Associated Peripheral Neuropathy

Drug Interactions and Antiretroviral Drug Monitoring

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page